Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12042139 | 1.00 | HRH3 (0.41) | HRH3CHRNA7HTR3ACRHBPCRHR2 | |
| SCHEMBL30407095 | 0.77 | SMN1; SMN2 (0.40) | HRH3CHRNA7HTR3AIRAK4 | |
| SCHEMBL29505262 | 0.77 | HRH3 (0.40) | HRH3CHRNA7HTR3ACRHBPCRHR2 | |
| SCHEMBL1661549 | 0.77 | SMN1; SMN2 (0.40) | HRH3CHRNA7HTR3AIRAK4 | |
| SCHEMBL113113 | 0.77 | RAB9A (0.40) | HRH3 | |
| SCHEMBL30136461 | 0.77 | RAB9A (0.40) | HRH3 | |
| SCHEMBL15597177 | 0.77 | HRH3 (0.40) | HRH3CHRNA7HTR3ACRHBPCRHR2 | |
| SCHEMBL7331057 | 0.77 | HRH3 (0.40) | HRH3CHRNA7HTR3ACRHBPCRHR2 | |
| SCHEMBL25382465 | 0.76 | HRH3 (0.38) | HRH3CHRNA7HTR3A | |
| SCHEMBL25381393 | 0.76 | HRH3 (0.38) | HRH3CHRNA7HTR3AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | ADH1A, ADH5, ADH1C | HRH3 1802/4885CHRNA7 1188/4885HTR3A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.